Jim Simons Dia Medica Therapeutics Inc. Transaction History

Renaissance Technologies LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$1.32 - $1.89 $40,773 - $58,380	30,889 Added 91.88%	64,508 $99,000
Q4 2022 Feb 13, 2023	BUY	$1.13 - $1.62 $37,989 - $54,462	33,619 New	33,619 $53,000
Q3 2021 Nov 12, 2021	SELL	$3.1 - $4.32 $291,710 - $406,512	-94,100 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$4.45 - $9.91 $262,550 - $584,690	-59,000 Reduced 38.54%	94,100 $419,000
Q1 2021 May 13, 2021	BUY	$7.76 - $10.43 $308,072 - $414,071	39,700 Added 35.01%	153,100 $1.4 Million
Q4 2020 Feb 10, 2021	BUY	$4.13 - $10.14 $71,862 - $176,436	17,400 Added 18.13%	113,400 $1.15 Million
Q3 2020 Nov 13, 2020	SELL	$3.91 - $7.15 $34,017 - $62,205	-8,700 Reduced 8.31%	96,000 $407,000
Q2 2020 Aug 13, 2020	BUY	$2.6 - $7.32 $205,012 - $577,189	78,851 Added 305.04%	104,700 $726,000
Q1 2020 May 14, 2020	BUY	$2.25 - $5.64 $58,160 - $145,788	25,849 New	25,849 $72,000

4.22M

8.2K

200

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $118M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.